ELderly REspiratory VIral Cohort

N/ANot Yet RecruitingNCT07813481

Assistance Publique - Hôpitaux de Paris1,000 enrolled

Overview

In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations. Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases. The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Influenza Viruses Respiratory Syncytial Virus (RSV)Severe Acute Respiratory Syndrome Coronavirus 2 Human Metapneumovirus (hMPV)Parainfluenza Virus (PIV)

Interventions

Respiratory viral infectionOTHER

Respiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient aged 65 years or older * Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4. * Hospitalized in an Acute Medicine/Geriatrics Unit * Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person. * Affiliated to a social security scheme Exclusion Criteria: * Refusal to participate * Patient deprived of liberty by a judicial or administrative decision

Outcomes

Primary Outcomes

Proportion of participants with death and/or organ decompensation at Day 180

Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.

Time frame: From baseline Day 0 to Day 180

Secondary Outcomes

Proportion of participants who died

Proportion of participants who died from any cause during follow-up.

Time frame: From baseline Day 0 to Day 30, Day 180, Day 365

Proportion of participants with major organ decompensation

Proportion of participants experiencing major decompensation of pre-existing comorbidities, including cardiac, renal, or respiratory decompensation.

Time frame: From baseline Day 0 to Day 30, Day 180, Day 365

Proportion of participants with unplanned hospital readmission

Proportion of participants experiencing an unplanned hospital readmission during follow-up.

Time frame: From baseline Day 0 to Day 30, Day 180, Day 365

Proportion of participants developing a lower respiratory tract infection

Proportion of participants developing a lower respiratory tract infection (LRTI) following the respiratory viral infection.

Time frame: From baseline Day 0 to Day 30

Change from baseline in functional dependency assessed by ADL and/or iADL scores

Change in functional dependency from baseline, assessed using the Activities of Daily Living (ADL) and/or Instrumental Activities of Daily Living (iADL) scores.

Time frame: Baseline Day 0, Day 30, Day 180, Day 365

Change from baseline in sarcopenia risk assessed by SARC-F score

Change in sarcopenia risk from baseline, assessed using the SARC-F score.

Time frame: Baseline Day 0, Day 30, Day 180, Day 365

Change from baseline in quality of life assessed by EQ-5D-3L

Change in health-related quality of life from baseline, assessed using the EQ-5D-3L questionnaire.

Time frame: Baseline Day 0, Day 30, Day 180, Day 365

Number and type of bacterial and viral co-infections

Number and type of bacterial and viral co-infections diagnosed at the same time as, or within seven days following, the occurrence of the first respiratory viral infection.

Time frame: Baseline Day 0 to D7

Change in respiratory viral load between Day 0 and Day 7

Change in viral load between Day 0 and Day 7 for each respiratory virus identified in study participants.

Time frame: From Day 0 to Day 7

Proportion of participants with death and/or major organ decompensation at Day 30

Proportion of participants who died and/or experienced major organ decompensation by Day 30. This outcome will be used to assess vaccine effectiveness for vaccine-preventable respiratory viral infections.

Time frame: From baseline Day 0 to Day 30

ELderly REspiratory VIral Cohort

Overview

Conditions

Interventions

Eligibility

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts